Randomized Comparison of Adjuvant Aromatase Inhibitor Exemestane plus Ovarian Function Suppression vs Tamoxifen plus Ovarian Function Suppression in Premenopausal.

Slides:



Advertisements
Similar presentations
Neoadjuvant Hormone Treatment of Breast Cancer H.S.A. Oldenburg E.J.Th. Rutgers J.M. Dixon symposium 29 juni 2005.
Advertisements

Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
Breast Cancer Systemic Therapy for Early Stage Disease
Obesity at Diagnosis Is Associated with Inferior Outcomes in Hormone Receptor Positive Breast Cancer 1 The Impact of Body Mass Index (BMI) on the Efficacy.
Choosing between different hormonal therapies Rudy Van den Broecke UZ Ghent.
Cancer Clinical Trials:
Department of Surgery, United Christian Hospital Aromatase Inhibitors Current Use in Breast Cancer JHGR 16 Jan 2005 Dr. Sharon Chan Department of Surgery,
Cancer Center Trials at St. Barnabas Medical Center.
Prevention of Early Menopause Study (POEMS)-S0230 Phase III trial of LHRH analog during chemotherapy to reduce ovarian failure in early stage, hormone.
Breast Plenary Abstracts How Do These Studies Impact Clinical Practice Today and in the Years Ahead? Presented By Eric Winer at 2014 ASCO Annual Meeting.
The Effect of Zoledronic Acid (ZOL) on Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Letrozole:
Long-Term Effects of Continuing Adjuvant Tamoxifen to 10 Years versus Stopping at 5 Years After Diagnosis of Oestrogen Receptor- Positive Breast Cancer:
These slides were released by the speaker for internal use by Novartis.
Investigator Meeting SOFT GOCCHI August 16, 2007 BIGBIG.
Day 2 Welcome Back ! 8.30 BIG 1-98 Issues 8.45 BIG 1-98 Syndicate The Case for Switching ITA & ARNO/ABCSG The Switch Call Video Statistics.
The Carry-Over Effect of Adjuvant Zoledronic Acid: Comparison of 48- and 62-Month Analyses of ABCSG-12 Suggests the Benefits of Combining Zoledronic Acid.
BIG 1-98/IBCSG Henning Mouridsen for the BIG 1-98 Collaborative Group Authors: Sunil Verma Date posted: December 22, 2008.
Best first ? The ATAC completed treatment analysis Professor Jack Cuzick Wolfson Institute of Preventive Medicine, London, UK.
Principles of Hormonal Therapy Justus Apffelstaedt University of Stellenbosch These Power Point presentations are free to download only for academic purposes,
Efficacy and Safety of Continued Zoledronic Acid every 4 Weeks versus every 12 Weeks in Women with Bone Metastases from Breast Cancer: Results of the OPTIMIZE-2.
Istituto Nazionale per la Ricerca sul Cancro Genoa – Italy
San Antonio Breast Cancer Symposium 2012 Helen K. Chew, MD, FACP Professor of Medicine.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year.
Neoadjuvant Endocrine Treatment in Breast Cancer Giorgio Mustacchi Centro Oncologico Università di Trieste.
Published online July 24, Aromatase inhibitors versus tamoxifen in early breast.
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial of lenvatinib (E7080) in patients with 131I-refractory differentiated thyroid.
A Randomized Phase 2 Trial Comparing Efficacy of the Combination of the PARP-inhibitor Olaparib and the Anti-angiogenic Cediranib Against Olaparib Alone.
A Comparison of Fulvestrant 500 mg with Anastrozole as First-line Treatment for Advanced Breast Cancer: Follow-up Analysis from the FIRST Study Robertson.
Extended adjuvant treatment with anastrozole: results from the ABCSG Trial 6a R Jakesz, H Samonigg, R Greil, M Gnant, M Schmid, W Kwasny, E Kubista, B.
Highlights of the Day-Plenary Session June 1, 2014 Lowell E. Schnipper, M.D. Presented By Lowell Schnipper at 2014 ASCO Annual Meeting.
Anastrozole (‘Arimidex’): a new standard of care?
‘Arimidex’, Tamoxifen, Alone or in Combination (ATAC) trial: Completed Treatment Analysis.
SNDA Letrozole (Femara®) Indication: First-line therapy in post- menopausal women with advanced breast cancer. Prior approval: Second-line therapy.
S1207: Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients.
Adjuvant ovarian suppression combined with tamoxifen or anastrozole, alone or in combination with zoledronic acid, in premenopausal.
Joanne Edwards Medical Information Manager ASCO Tech Assessment Update Commercial Implications & Promotional Guidance.
Lectures inEarly Breast Cancer A PowerPoint slide set based on images from: Lectures in Early Breast Cancer Part 3: Adjuvant Therapy in Early Breast Cancer.
Treatment Options for Premenopausal Women With Early-Stage Hormone Receptor–Positive Breast Cancer Ongoing Studies This program is supported by an educational.
Treatment Options for Postmenopausal Women With Early-Stage Hormone Receptor–Positive Breast Cancer Recent Trials and Future Directions Harold Burstein,
Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta- analysis of the randomised trials The Lancet Volume 386, Issue 10001,
Patterns of care and comparative effectiveness of endocrine therapy for premenopausal women with early breast cancer A multi-institution cohort study February.
J Clin Oncol 30: R2 윤경한 / Prof. 김시영 Huan Jin, Dongsheng Tu, Naiqing Zhao, Lois E. Shepherd, and Paul E. Goss.
MA.17R: Reduced Risk of Recurrence With Extending Adjuvant Letrozole Beyond 5 Yrs in Postmenopausal Women With Early-Stage Breast Cancer CCO Independent.
Presented By Shin Fujita at 2016 ASCO Annual Meeting
Angelo Di Leo “Sandro Pitigliani” Medical Oncology Department Hospital of Prato Istituto Toscano Tumori, Prato, Italy Adjuvant hormone therapy in post-menopausal.
Angelo Di Leo “Sandro Pitigliani” Medical Oncology Department Hospital of Prato Istituto Toscano Tumori, Prato, Italy Adjuvant hormone therapy in pre-menopausal.
AROMATASE INHIBITORS.
Phase III SOLE: Continuous vs Intermittent Extended Letrozole After Adjuvant Endocrine Therapy in Early HR+ Breast Cancer CCO Independent Conference Highlights*
CCO Independent Conference Coverage
Securing the cure in resectable lung cancer
JOURNAL OF CLINICAL ONCOLOGY 25:
Presented By Mette Van Ramshorst at 2017 ASCO Annual Meeting
Presented By Marco Colleoni at 2017 ASCO Annual Meeting
Presented By Luca Malorni at 2017 ASCO Annual Meeting
CCO Independent Conference Coverage
S1207: Phase III randomized, placebo-controlled trial adding 1 year of everolimus to adjuvant endocrine therapy for patients with high-risk, HR+, HER2-
SAFETY AND EFFICACY OF EVEROLIMUS PLUS EXEMESTANE IN METASTATIC BREAST CANCER BEYOND THE SECOND LINE TREATMENT: A SINGLE INSTITUTION EXPERIENCE M. Giampaglia,
The Nurse View: Hormone Receptor-Positive Advanced Breast Cancer
Overall Program Goals. Overall Program Goals Current Approaches.
Optimizing Targeted Therapy for HER2-Positive Advanced Breast Cancer: First-line Considerations.
Treatment of HR+ Breast Cancer: A Clinical Update
The Research Question RESEARCH METHOD
Introduction Advanced Hormone Receptor-Positive Breast Cancer
ABSTRACT ABCSG 6a MA17-1 MA.17R NSABP B-33. Extended Adjuvant Therapy With Aromatase Inhibitor Among Postmenopausal Breast Cancer.
Volume 386, Issue 10001, Pages (October 2015)
ONCOLOGYEDUCATION.COM ARTICLE SUMMARIES
Adjuvant Ovarian Suppression in Premenopausal Breast Cancer
Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials 
20-Year Risks of Breast-Cancer Recurrence
Fertility Preservation in Breast Cancer
Presentation transcript:

Randomized Comparison of Adjuvant Aromatase Inhibitor Exemestane plus Ovarian Function Suppression vs Tamoxifen plus Ovarian Function Suppression in Premenopausal Women with Hormone Receptor Positive Early Breast Cancer: Joint Analysis of IBCSG TEXT and SOFT Presented By Olivia Pagani at 2014 ASCO Annual Meeting

TEXT and SOFT Presented By Olivia Pagani at 2014 ASCO Annual Meeting

TEXT and SOFT Worldwide Collaborative Presented By Olivia Pagani at 2014 ASCO Annual Meeting

Premenopausal Endocrine Therapy Presented By Olivia Pagani at 2014 ASCO Annual Meeting

TEXT - SOFT Trials Aromatase Inhibitor Question Presented By Olivia Pagani at 2014 ASCO Annual Meeting

TEXT and SOFT Designs Presented By Olivia Pagani at 2014 ASCO Annual Meeting

Eligibility Presented By Olivia Pagani at 2014 ASCO Annual Meeting

Treatments Presented By Olivia Pagani at 2014 ASCO Annual Meeting

Study Procedures Presented By Olivia Pagani at 2014 ASCO Annual Meeting

Endpoints Presented By Olivia Pagani at 2014 ASCO Annual Meeting

Statistical Considerations Presented By Olivia Pagani at 2014 ASCO Annual Meeting

Characteristics Presented By Olivia Pagani at 2014 ASCO Annual Meeting

Exemestane+OFS Improved DFS Presented By Olivia Pagani at 2014 ASCO Annual Meeting

Sites of First Failure Presented By Olivia Pagani at 2014 ASCO Annual Meeting

Exemestane+OFS Reduced Recurrence Presented By Olivia Pagani at 2014 ASCO Annual Meeting

Women Who Did Not Receive Chemotherapy Presented By Olivia Pagani at 2014 ASCO Annual Meeting

Women Who Received Chemotherapy Presented By Olivia Pagani at 2014 ASCO Annual Meeting

Selected Adverse Events Presented By Olivia Pagani at 2014 ASCO Annual Meeting

Adverse Events and QOL Presented By Olivia Pagani at 2014 ASCO Annual Meeting

Conclusions Presented By Olivia Pagani at 2014 ASCO Annual Meeting

More from TEXT and SOFT Presented By Olivia Pagani at 2014 ASCO Annual Meeting

Slide 22 Presented By Olivia Pagani at 2014 ASCO Annual Meeting

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.